There are also reports of upregulation of Axl in anti-HER2-resistant breast cancer, unitinib-resistant renal cell cancer [160], and anaplastic lymphoma kinase (ALK) inhibitor-resistant neuroblastoma [138,161], as well as in head and neck cancer resistant to PI3K inhibitors [149]. Here, AXL is linked to breast carcinoma.